EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

CRISPR Interference to Inhibit Oncogenes for Cancer Therapy

Bin Guo iD

International Journal of Molecular Sciences · 16.04.2026 · 27 (8) · 3564

DOI: 10.3390/ijms27083564 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 16.04.2026. Verfasst von Bin Guo. Beteiligte Einrichtung: Department of Pharmacological and Pharmaceutical Sciences, University of Houston, Houston, TX 77204, USA. Hauptthemen laut MEDLINE: Neoplasms, Oncogenes, CRISPR-Cas Systems, Genetic Therapy. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 101 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIH HHS, National Institute of Health.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

CRISPR interference (CRISPRi), a programmable transcriptional repression technology derived from nuclease-deficient CRISPR-Cas systems, has emerged as a powerful method for selectively inhibiting oncogene expression without altering the genomic DNA. This feature offers a major advantage over other oncogene targeting technologies such as CRISPR-mediated gene knockout, mRNA inhibition by siRNA or miRNA, or small-molecule inhibitors of the proteins encoded by the oncogenes, especially in cancers driven by transcriptional dysregulation or otherwise undruggable oncogenes. Here, I present a comprehensive review of CRISPRi mechanisms, delivery strategies, and preclinical applications in oncology (including advances in targeting core oncogenic drivers like MYC and KRAS). The advantages of CRISPRi as well as in vivo validation of CRISPRi-mediated tumor suppression are discussed. Finally, I outline translational challenges and future directions for incorporating CRISPRi into precision cancer therapies. The accumulated evidence suggests that CRISPRi could become a cornerstone for next-generation gene-regulatory therapeutics.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

NeoplasmsOncogenesCRISPR-Cas SystemsGenetic TherapyHumansAnimalsGene Editing

Stichwörter der Autor:innen

CRISPR interferenceCRISPR-CasCRISPRicancer therapygene deliverygene silencingoncogenes

Autor:innen und Institutionen

  • Department of Pharmacological and Pharmaceutical Sciences, University of Houston, Houston, TX 77204, USA.

ORCID-Profile: Bin Guo

Förderung

  • NIH HHS
  • National Institute of Health

Zitieren

APA

Guo, B. (2026). CRISPR Interference to Inhibit Oncogenes for Cancer Therapy. International Journal of Molecular Sciences, 27(8), 3564. https://doi.org/10.3390/ijms27083564

Vancouver

Guo B. CRISPR Interference to Inhibit Oncogenes for Cancer Therapy. International Journal of Molecular Sciences. 2026;27(8):3564. doi:10.3390/ijms27083564

BibTeX
@article{Guo2026,
  author = {Guo, Bin},
  title = {CRISPR Interference to Inhibit Oncogenes for Cancer Therapy},
  journal = {International Journal of Molecular Sciences},
  year = {2026},
  volume = {27},
  number = {8},
  pages = {3564},
  doi = {10.3390/ijms27083564}
}
Kostenlos starten →